### Children's Mercy Kansas City

### SHARE @ Children's Mercy

**Posters** 

11-2021

### A case of an elevated tryptase

Sonya Parashar Children's Mercy Hopital

Nikita Raje Children's Mercy Hospital

Let us know how access to this publication benefits you

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/posters



Part of the Allergy and Immunology Commons, and the Pediatrics Commons

### **Recommended Citation**

Parashar, Sonya and Raje, Nikita, "A case of an elevated tryptase" (2021). Posters. 242. https://scholarlyexchange.childrensmercy.org/posters/242

This Poster is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Posters by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact histeel@cmh.edu.

# A case of an elevated tryptase (9122)

Sonya Parashar, MD<sup>1,2</sup> Nikita Raje, MD<sup>1,2</sup>

<sup>1</sup>Children's Mercy Kansas City <sup>2</sup>University of Missouri Kansas City

## Background

- Hereditary Alpha Tryptasemia (HaT) is autosomal dominant disorder characterized by elevated baseline tryptase (8 ng/ml or greater) and increased copies of a-tryptase alleles
- Occurs in 3% of the population and more common in female patients

# Case presentation

- A full term, 13-month-old female patient presented to clinic for an elevated tryptase
- Past medical history: gastroesophageal reflux disease
- Past surgical history: none
- Family history: older sister with history of flushing. She eventually had a negative evaluation for mastocytosis
- Medications: none

### Case presentation (cont.) and evaluation

	Presentation	6-mo F/U	9-mo F/U	12-mo F/U
Symptoms		increased night awakenings, and constipation (no	of loose stools,	Symptoms controlled
Tryptase (ng/ml)	13.0	11.7	12.2	
Other labs	CBC with thrombocytosis and eosinophilia and peripheral blood <i>c-kit</i> D816V negative	CBC normalized	for copy number variants of	Microarray showed extra allelic alpha- tryptase at <i>TPSAB1</i>
Attempted treatment	Cetirizine as needed + epinephrine autoinjector	Added cromolyn	dose adjusted	Continue cetirizine and cromolyn

### Management

- Diagnosis is made based on symptoms, serum tryptase level, and genetic testing
- Treatment is supportive in nature and includes maximally tolerated H1 and H2 histamine blockers as well as cromolyn for gastrointestinal symptoms
- In patients with HaT and known hypersensitivity, epinephrine autoinjector is recommended.

### Conclusion

- Given a higher prevalence than systematic mastocytosis, one must have a high degree of suspicion for HaT to include in one's differential diagnoses
- Number of allelic copies of alpha tryptase correlates with symptom severity

### References

1.Carrigan, C. Usefulness of testing for hereditary alpha tryptasemia in symptomatic patients with elevated tryptase *JACI In Practice*. 2020;8(6):2066-2067. doi:<a href="https://doi.org/10.1016/j.jaip.2020.01.012">https://doi.org/10.1016/j.jaip.2020.01.012</a>
2.Giannetti, M. Hereditary alpha-tryptasemia in 101 patients with mast cell activation-related symptomatology including aparbylaxis. *App. Allergy, Asthma. Immunol.* 2021: in press. doi: https://doi.org/10.1016/j.apai.2021.01.016

2.Giannetti, M. Hereditary alpha-tryptasemia in 101 patients with mast cell activation-related symptomatology including anaphylaxis. *Ann Allergy Asthma Immunol.* 2021; in press. doi:https://doi.org/10.1016/j.anai.2021.01.016 3.Le QT, Lyons JJ, Naranjo AN, et al. Impact of naturally forming human α/β-tryptase heterotetramers in the pathogenesis of hereditary α-tryptasemia. *J Exp Med.* 2019;216(10):2348-2361. doi:10.1084/jem.20190701 4.Lyons, JJ. Hereditary Alpha Tryptasemia: Genotyping and Associated Clinical Features. *Immunol Allergy Clin North Am.* 2018;38(3):483-495. doi:10.1016/j.iac.2018.04.003

5. Weiler, C. AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management. *JACI*. 2019;144 (4): 883-896. doi: <a href="https://doi.org/10.1016/j.jaci.2019.08.023">https://doi.org/10.1016/j.jaci.2019.08.023</a>

